1. Alberts DS, Surwit EA, Mei Peng Y, McCloskey T, Graham V, Roe D: Phase I and Pharmacokinetic Study of Mitoxantrone by Intraperitoneal Administration, in Seeber S, Aigner KR (eds): Die Iokoregionale Tumortherapie. Berlin Walter de Gruyter, 1988, p. 39–49.
2. Dedrick RL, Myers CE, Burnagy PM, De Vita VT jr.: Pharmacokinetic Rationale for Peritoneal Drug Administration in the Treatment of Ovarian Cancer. Cancer Treat Rep 1978;62:111.
3. Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Ohta M, Takahashi M, Kitsukawa Y, Mizutani M, Chikenji T, Okui K: Positive Results of Combined Therapy of Surgery and Intraperitoneal Hyperthermic Perfusion for Far-Advanced Gastric Cancer. Ann Surg 1990;212:592–596.
4. Fujimoto S, Takahashi M, Kobayashi K, Mutou T, Kure M, Masaoka H, Ohkubo H: Antitumor efficacy of intraperitoneal hyperthermochemotherapy combined with aggressive surgery for patients with advanced gastric cancer, in Banzet P, Holland JF, Khayat D, Weil M (eds). Cancer treatment—an update. Paris, Springer 1994, p 665–668.
5. Gyves JW, Ensminger WD, Niederhuber JE Manuzak P, van Harken D, Janis MA, Stetson P, Knutsen C, Doan K: Phase I Study of Intraperitoneal 5 Day Continuous 5-FU Infusion and Bolus Mitomycin C. Proc ASCO 1982:15 (abstr).